IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Dec 5, 2025, 4:00 PM EST
1.770
-0.020 (-1.12%)
After-hours: Dec 5, 2025, 5:47 PM EST
IN8bio Employees
IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.
Employees
18
Change (1Y)
-13
Growth (1Y)
-41.94%
Revenue / Employee
n/a
Profits / Employee
-$1,147,667
Market Cap
8.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INAB News
- 4 weeks ago - IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewsWire
- 5 weeks ago - IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications - GlobeNewsWire
- 4 months ago - IN8bio (INAB) Q2 Loss Narrows 77% - The Motley Fool
- 4 months ago - IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 months ago - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewsWire
- 6 months ago - IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival - GlobeNewsWire
- 7 months ago - IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 - GlobeNewsWire